338 related articles for article (PubMed ID: 30165490)
1. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
[TBL] [Abstract][Full Text] [Related]
2. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
Rivera-Nieves J
Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
[TBL] [Abstract][Full Text] [Related]
3. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Panés J; Salas A
J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
[TBL] [Abstract][Full Text] [Related]
4. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
5. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
[TBL] [Abstract][Full Text] [Related]
6. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
7. Interfering with leukocyte trafficking in Crohn's disease.
Biswas S; Bryant RV; Travis S
Best Pract Res Clin Gastroenterol; 2019; 38-39():101617. PubMed ID: 31327399
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
Sands BE
Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
[TBL] [Abstract][Full Text] [Related]
9. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.
Bamias G; Clark DJ; Rivera-Nieves J
Curr Drug Targets; 2013 Nov; 14(12):1490-500. PubMed ID: 23621509
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Yarur A; Giles DA; Yeasmin S; Lundborg L; Sandborn WJ; Patel DR; Rivera-Nieves J
Front Pharmacol; 2019; 10():212. PubMed ID: 30930775
[TBL] [Abstract][Full Text] [Related]
12. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
13. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
Cesarini M; Fiorino G
Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
16. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
17. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Wyatt NJ; Speight RA; Stewart CJ; Kirby JA; Lamb CA
BioDrugs; 2021 Sep; 35(5):473-503. PubMed ID: 34613592
[TBL] [Abstract][Full Text] [Related]
18. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
Zundler S; Becker E; Schulze LL; Neurath MF
Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
[TBL] [Abstract][Full Text] [Related]
19. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Therapeutics for IBD.
Löwenberg M; D'Haens G
Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
